Share Price and Basic Stock Data
Last Updated: December 5, 2025, 3:19 am
| PEG Ratio | 0.57 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajooni Biotech Ltd operates within the animal feed sector, focusing primarily on shrimp feed. As of the latest available data, the company reported a market capitalization of ₹78.5 Cr and a share price of ₹4.56. In terms of revenue, Ajooni Biotech recorded sales of ₹74 Cr for the fiscal year ending March 2023, with an anticipated rise to ₹80 Cr in March 2024 and further increasing to ₹115 Cr by March 2025. Quarterly sales have shown fluctuations, with a notable spike to ₹41.26 Cr in March 2023, followed by a decline to ₹19.48 Cr in September 2023. This volatility indicates a potential challenge in maintaining consistent revenue streams, which may be influenced by market dynamics and operational efficiency. The company’s operating profit margin (OPM) stood at a modest 2.27%, suggesting competitive pressures within the industry. The trailing twelve months (TTM) revenue stood at ₹120 Cr, reflecting a growing operational footprint but also highlighting the need for improved revenue management strategies.
Profitability and Efficiency Metrics
Profitability metrics for Ajooni Biotech reveal a mixed performance. The company reported a net profit of ₹4 Cr for the fiscal year ending March 2023, with a profit before tax of ₹3 Cr. However, the operating profit has shown volatility, peaking at ₹0.94 Cr in March 2023 before declining to a loss of ₹0.65 Cr in December 2023. The company’s return on equity (ROE) was reported at 5.15%, while the return on capital employed (ROCE) stood at 6.91%. These figures are generally considered low in comparison to the sector averages, indicating potential inefficiencies in capital utilization. Furthermore, the cash conversion cycle (CCC) of 129 days poses a risk to liquidity, suggesting that the company takes a considerable amount of time to convert its investments in inventory and other resources into cash flows. This extended CCC may hinder operational agility and financial performance, necessitating a review of inventory management and receivables collection processes.
Balance Sheet Strength and Financial Ratios
Ajooni Biotech’s balance sheet reveals a relatively stable financial position, with total reserves of ₹55 Cr against borrowings of ₹9 Cr. This low level of debt provides a safety net, reflected in an interest coverage ratio (ICR) of 17.22x, indicating the company can comfortably meet its interest obligations. The price-to-book value (P/BV) ratio stood at 1.10x, suggesting the stock is fairly valued compared to its book value. However, the company’s current ratio of 12.86x indicates a strong liquidity position, which is significantly higher than typical sector ranges, providing a cushion against short-term liabilities. The debt-to-equity ratio at 0.06x is also low, indicating prudent financial management. Nevertheless, the decline in net profit margins, which stood at 2.94% for the fiscal year ending March 2025, highlights the need for improved cost control measures to enhance profitability in a competitive market.
Shareholding Pattern and Investor Confidence
The shareholding structure of Ajooni Biotech Ltd reflects a predominance of public ownership, which accounted for 73.11% as of March 2025. Promoter holdings have seen a gradual decline from 36.39% in December 2022 to 26.89% by March 2025, which may raise concerns regarding insider confidence in the company’s future prospects. Foreign institutional investors (FIIs) have shown negligible interest, holding 0% of shares, while domestic institutional investors (DIIs) have not been reported. The total number of shareholders has increased significantly, from 16,429 in December 2022 to 64,305 by March 2025, indicating growing interest from retail investors. This increase in the shareholder base may enhance market liquidity but also suggests a reliance on retail sentiment for price stability. The decreasing promoter stake could impact long-term investor confidence, necessitating clear communication regarding the company’s strategic direction and growth plans.
Outlook, Risks, and Final Insight
Looking ahead, Ajooni Biotech faces both opportunities and challenges. The anticipated growth in sales to ₹115 Cr by March 2025 presents a positive outlook, driven by potential market expansion and product innovation. However, risks such as fluctuating profitability, highlighted by recent operating losses, and a prolonged cash conversion cycle could impede financial stability. The company must address operational inefficiencies and enhance its cost management strategies to convert revenue growth into sustainable profits. Furthermore, the declining promoter holding raises concerns about governance and long-term strategic vision, which could affect market perception. To navigate these challenges, Ajooni Biotech may consider strategic partnerships or diversification to strengthen its market position. In summary, while the company exhibits growth potential, focused efforts on operational efficiency and investor relations are essential for sustaining long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ajooni Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Narmada Agrobase Ltd | 86.3 Cr. | 22.7 | 28.4/14.6 | 22.5 | 15.3 | 0.00 % | 13.0 % | 11.2 % | 10.0 |
| Godrej Agrovet Ltd | 11,295 Cr. | 587 | 876/560 | 25.9 | 94.1 | 1.87 % | 16.6 % | 17.7 % | 10.0 |
| Avanti Feeds Ltd | 11,148 Cr. | 818 | 965/572 | 18.0 | 221 | 1.10 % | 24.0 % | 19.5 % | 1.00 |
| Ajooni Biotech Ltd | 78.5 Cr. | 4.56 | 8.55/4.16 | 19.7 | 5.21 | 0.00 % | 6.91 % | 5.15 % | 2.00 |
| Industry Average | 11,221.50 Cr | 358.07 | 21.53 | 83.90 | 0.74% | 15.13% | 13.39% | 5.75 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.31 | 10.29 | 10.63 | 41.26 | 21.00 | 19.48 | 20.05 | 19.58 | 25.66 | 25.72 | 34.03 | 29.27 | 31.27 |
| Expenses | 11.55 | 9.70 | 10.15 | 40.32 | 20.34 | 18.85 | 20.70 | 17.99 | 24.70 | 24.95 | 33.10 | 28.26 | 30.56 |
| Operating Profit | 0.76 | 0.59 | 0.48 | 0.94 | 0.66 | 0.63 | -0.65 | 1.59 | 0.96 | 0.77 | 0.93 | 1.01 | 0.71 |
| OPM % | 6.17% | 5.73% | 4.52% | 2.28% | 3.14% | 3.23% | -3.24% | 8.12% | 3.74% | 2.99% | 2.73% | 3.45% | 2.27% |
| Other Income | 0.01 | 0.00 | 0.02 | 0.26 | 0.07 | 0.29 | 1.57 | 0.26 | 0.04 | 0.31 | 0.39 | 1.34 | 0.65 |
| Interest | 0.10 | 0.13 | 0.13 | 0.12 | 0.13 | 0.19 | 0.12 | 0.11 | 0.15 | 0.06 | 0.07 | 0.06 | 0.08 |
| Depreciation | 0.25 | 0.25 | 0.26 | 0.24 | 0.21 | 0.21 | 0.21 | 0.24 | 0.22 | 0.23 | 0.24 | 0.38 | 0.25 |
| Profit before tax | 0.42 | 0.21 | 0.11 | 0.84 | 0.39 | 0.52 | 0.59 | 1.50 | 0.63 | 0.79 | 1.01 | 1.91 | 1.03 |
| Tax % | 23.81% | 19.05% | 0.00% | 35.71% | -2.56% | 23.08% | 23.73% | 38.67% | 25.40% | 22.78% | 27.72% | 19.37% | 24.27% |
| Net Profit | 0.32 | 0.16 | 0.11 | 0.54 | 0.40 | 0.40 | 0.44 | 0.91 | 0.47 | 0.62 | 0.73 | 1.54 | 0.78 |
| EPS in Rs | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.03 | 0.04 | 0.04 | 0.09 | 0.05 |
Last Updated: August 20, 2025, 2:35 pm
Below is a detailed analysis of the quarterly data for Ajooni Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 31.27 Cr.. The value appears strong and on an upward trend. It has increased from 29.27 Cr. (Mar 2025) to 31.27 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Jun 2025, the value is 30.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.26 Cr. (Mar 2025) to 30.56 Cr., marking an increase of 2.30 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.71 Cr.. The value appears to be declining and may need further review. It has decreased from 1.01 Cr. (Mar 2025) to 0.71 Cr., marking a decrease of 0.30 Cr..
- For OPM %, as of Jun 2025, the value is 2.27%. The value appears to be declining and may need further review. It has decreased from 3.45% (Mar 2025) to 2.27%, marking a decrease of 1.18%.
- For Other Income, as of Jun 2025, the value is 0.65 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Mar 2025) to 0.65 Cr., marking a decrease of 0.69 Cr..
- For Interest, as of Jun 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.38 Cr. (Mar 2025) to 0.25 Cr., marking a decrease of 0.13 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.03 Cr.. The value appears to be declining and may need further review. It has decreased from 1.91 Cr. (Mar 2025) to 1.03 Cr., marking a decrease of 0.88 Cr..
- For Tax %, as of Jun 2025, the value is 24.27%. The value appears to be increasing, which may not be favorable. It has increased from 19.37% (Mar 2025) to 24.27%, marking an increase of 4.90%.
- For Net Profit, as of Jun 2025, the value is 0.78 Cr.. The value appears to be declining and may need further review. It has decreased from 1.54 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.76 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to 0.05, marking a decrease of 0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 4:16 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 7 | 13 | 29 | 42 | 40 | 40 | 51 | 74 | 74 | 80 | 115 | 120 |
| Expenses | 1 | 7 | 13 | 28 | 41 | 39 | 39 | 49 | 71 | 72 | 78 | 111 | 117 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 4 | 3 |
| OPM % | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 3% | 4% | 4% | 3% | 3% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 |
| Tax % | 0% | 27% | 29% | 28% | 20% | 15% | 29% | 26% | 28% | 28% | 28% | 22% | |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 |
| EPS in Rs | 0.02 | 0.12 | 0.18 | 0.36 | 0.03 | 0.03 | 0.02 | 0.02 | 0.05 | 0.06 | 0.12 | 0.20 | 0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% |
Ajooni Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 47% |
| 5 Years: | 56% |
| 3 Years: | 47% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -19% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 4, 2025, 9:40 pm
Balance Sheet
Last Updated: December 4, 2025, 12:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.24 | 0.24 | 0.24 | 0.33 | 6 | 6 | 8 | 10 | 10 | 18 | 18 | 34 | 34 |
| Reserves | 0 | 0 | 0 | 1 | 5 | 6 | 7 | 6 | 6 | 24 | 25 | 54 | 55 |
| Borrowings | 0 | 0 | 1 | 1 | 5 | 5 | 5 | 7 | 5 | 5 | 2 | 2 | 9 |
| Other Liabilities | 0 | 1 | 1 | 11 | 4 | 1 | 2 | 6 | 7 | 12 | 3 | 5 | 5 |
| Total Liabilities | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
| Fixed Assets | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 | 6 | 6 | 10 | 11 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 11 |
| Investments | 0 | 0 | 0 | 6 | 6 | 4 | 3 | 1 | 1 | 4 | 2 | 3 | 3 |
| Other Assets | 0 | 1 | 2 | 6 | 12 | 13 | 18 | 22 | 22 | 48 | 34 | 80 | 78 |
| Total Assets | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
Below is a detailed analysis of the balance sheet data for Ajooni Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 34.00 Cr..
- For Reserves, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 78.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 78.00 Cr., marking a decrease of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
Notably, the Reserves (55.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | -1.00 | 0.00 | -4.00 | -4.00 | -4.00 | -5.00 | -2.00 | -2.00 | 0.00 | 2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 40 | 33 | 17 | 25 | 44 | 115 | 98 | 68 | 101 | 59 | 52 |
| Inventory Days | 141 | 22 | 14 | 63 | 19 | 51 | 34 | 46 | 34 | 39 | 80 | 90 |
| Days Payable | 100 | 66 | 27 | 79 | 9 | 12 | 20 | 46 | 39 | 56 | 8 | 13 |
| Cash Conversion Cycle | 99 | -4 | 20 | 1 | 35 | 84 | 129 | 98 | 63 | 83 | 131 | 129 |
| Working Capital Days | 96 | 5 | 9 | -29 | -1 | 84 | 105 | 77 | 58 | 94 | 132 | 160 |
| ROCE % | 28% | 18% | 37% | 10% | 4% | 4% | 5% | 9% | 6% | 8% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Diluted EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Cash EPS (Rs.) | 0.25 | 0.34 | 0.24 | 2.16 | 0.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Revenue From Operations / Share (Rs.) | 6.66 | 9.14 | 8.50 | 74.00 | 51.01 |
| PBDIT / Share (Rs.) | 0.33 | 0.50 | 0.34 | 3.11 | 1.66 |
| PBIT / Share (Rs.) | 0.27 | 0.40 | 0.23 | 2.00 | 1.09 |
| PBT / Share (Rs.) | 0.25 | 0.34 | 0.17 | 1.46 | 0.50 |
| Net Profit / Share (Rs.) | 0.19 | 0.24 | 0.12 | 1.05 | 0.37 |
| PBDIT Margin (%) | 5.01 | 5.52 | 4.10 | 4.20 | 3.26 |
| PBIT Margin (%) | 4.06 | 4.43 | 2.75 | 2.70 | 2.13 |
| PBT Margin (%) | 3.77 | 3.73 | 2.11 | 1.97 | 0.98 |
| Net Profit Margin (%) | 2.94 | 2.69 | 1.50 | 1.41 | 0.73 |
| Return on Networth / Equity (%) | 3.82 | 5.06 | 2.69 | 6.40 | 2.38 |
| Return on Capital Employeed (%) | 5.16 | 7.98 | 4.72 | 10.55 | 6.20 |
| Return On Assets (%) | 3.54 | 4.54 | 1.91 | 3.61 | 1.33 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.04 | 0.15 | 0.12 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.12 | 0.32 | 0.43 |
| Asset Turnover Ratio (%) | 1.61 | 1.51 | 1.70 | 2.60 | 2.00 |
| Current Ratio (X) | 12.86 | 10.74 | 2.28 | 2.18 | 2.05 |
| Quick Ratio (X) | 7.89 | 5.63 | 1.82 | 1.60 | 1.53 |
| Inventory Turnover Ratio (X) | 5.83 | 6.25 | 10.27 | 11.35 | 10.01 |
| Interest Coverage Ratio (X) | 17.22 | 7.95 | 6.40 | 5.76 | 2.85 |
| Interest Coverage Ratio (Post Tax) (X) | 11.09 | 4.88 | 3.35 | 2.94 | 1.64 |
| Enterprise Value (Cr.) | 95.06 | 53.43 | 39.48 | 72.63 | 36.96 |
| EV / Net Operating Revenue (X) | 0.82 | 0.66 | 0.52 | 0.98 | 0.72 |
| EV / EBITDA (X) | 16.51 | 12.07 | 12.90 | 23.34 | 22.19 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| Price / BV (X) | 1.10 | 1.21 | 0.83 | 4.11 | 1.94 |
| Price / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| EarningsYield | 0.03 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ajooni Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.66. It has decreased from 9.14 (Mar 24) to 6.66, marking a decrease of 2.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.50 (Mar 24) to 0.33, marking a decrease of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.27, marking a decrease of 0.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.25. This value is within the healthy range. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 2. It has decreased from 0.24 (Mar 24) to 0.19, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 5.01. This value is below the healthy minimum of 10. It has decreased from 5.52 (Mar 24) to 5.01, marking a decrease of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 10. It has decreased from 4.43 (Mar 24) to 4.06, marking a decrease of 0.37.
- For PBT Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 10. It has increased from 3.73 (Mar 24) to 3.77, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 2.69 (Mar 24) to 2.94, marking an increase of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 15. It has decreased from 5.06 (Mar 24) to 3.82, marking a decrease of 1.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.16. This value is below the healthy minimum of 10. It has decreased from 7.98 (Mar 24) to 5.16, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 3.54. This value is below the healthy minimum of 5. It has decreased from 4.54 (Mar 24) to 3.54, marking a decrease of 1.00.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.61. It has increased from 1.51 (Mar 24) to 1.61, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 12.86. This value exceeds the healthy maximum of 3. It has increased from 10.74 (Mar 24) to 12.86, marking an increase of 2.12.
- For Quick Ratio (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 2. It has increased from 5.63 (Mar 24) to 7.89, marking an increase of 2.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has decreased from 6.25 (Mar 24) to 5.83, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.22. This value is within the healthy range. It has increased from 7.95 (Mar 24) to 17.22, marking an increase of 9.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 11.09, marking an increase of 6.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 95.06. It has increased from 53.43 (Mar 24) to 95.06, marking an increase of 41.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.82, marking an increase of 0.16.
- For EV / EBITDA (X), as of Mar 25, the value is 16.51. This value exceeds the healthy maximum of 15. It has increased from 12.07 (Mar 24) to 16.51, marking an increase of 4.44.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has decreased from 1.21 (Mar 24) to 1.10, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajooni Biotech Ltd:
- Net Profit Margin: 2.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.16% (Industry Average ROCE: 15.13%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.82% (Industry Average ROE: 13.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.7 (Industry average Stock P/E: 21.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.94%
Fundamental Analysis of Ajooni Biotech Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Animal/Shrimp Feed | D-118, Industrial Area, Phase - VII, Mohali Punjab 160055 | info@ajoonibiotech.com http://www.ajoonibiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jasjot Singh | Managing Director |
| Mr. Gursimran Singh | Whole Time Director |
| Mr. Partek Singh | Director |
| Mr. Ramandeep Singh | Independent Director |
| Mr. Imteshwar Singh | Independent Director |
| Ms. Simmi Chabbra | Independent Woman Director |
Ajooni Biotech Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹6.50 |
| Previous Day | ₹6.50 |
FAQ
What is the intrinsic value of Ajooni Biotech Ltd?
Ajooni Biotech Ltd's intrinsic value (as of 05 December 2025) is 4.31 which is 5.48% lower the current market price of 4.56, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 78.5 Cr. market cap, FY2025-2026 high/low of 8.55/4.16, reserves of ₹55 Cr, and liabilities of 104 Cr.
What is the Market Cap of Ajooni Biotech Ltd?
The Market Cap of Ajooni Biotech Ltd is 78.5 Cr..
What is the current Stock Price of Ajooni Biotech Ltd as on 05 December 2025?
The current stock price of Ajooni Biotech Ltd as on 05 December 2025 is 4.56.
What is the High / Low of Ajooni Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajooni Biotech Ltd stocks is 8.55/4.16.
What is the Stock P/E of Ajooni Biotech Ltd?
The Stock P/E of Ajooni Biotech Ltd is 19.7.
What is the Book Value of Ajooni Biotech Ltd?
The Book Value of Ajooni Biotech Ltd is 5.21.
What is the Dividend Yield of Ajooni Biotech Ltd?
The Dividend Yield of Ajooni Biotech Ltd is 0.00 %.
What is the ROCE of Ajooni Biotech Ltd?
The ROCE of Ajooni Biotech Ltd is 6.91 %.
What is the ROE of Ajooni Biotech Ltd?
The ROE of Ajooni Biotech Ltd is 5.15 %.
What is the Face Value of Ajooni Biotech Ltd?
The Face Value of Ajooni Biotech Ltd is 2.00.